National Institute for Health and Care Excellence guidance means people with type 2 diabetes will be offered SGLT-2 inhibitors, known as flozins much earlier in their treatment. In addition, the NHS is set to save money because the most prescribed SGLT-2 medicine, dapagliflozin is now available as a clinically equivalent generic version.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.
Networks can be open to all or available only to a closed group defined by the administrator.
Join or create a network here.
